Decera Clinical Education Neuroscience Podcast · Decera Clinical Education

Beyond the Podium: Continuing the Q&A on Schizophrenia

·36 min·2 clips

Dr. Jonathan Meyer joins host Lisa Phipps to answer follow-up questions from a recent psychopharmacology conference talk on schizophrenia. The conversation covers the appropriate use of xanomeline-trospium (KarXT) across related psychiatric conditions (schizoaffective disorder, schizophreniform, delusional disorder, Parkinson's disease psychosis, Alzheimer's), drug combinations including clozapine and antidepressants, pregnancy and lactation considerations, pediatric and geriatric dosing, and strategies to manage pro-cholinergic nausea. Meyer also discusses the future of muscarinic agonist therapy and the possibility of a long-acting injectable formulation.

As heard by us

A careful Q and A on schizophrenia treatment, clozapine, and where a muscarinic option may fit.

The episode keeps its attention on schizophrenia treatment and uses the follow-up Q and A to work through where a muscarinic option may fit, both alongside other antipsychotics and in patients who are still only partly controlled.

Read the full review in PlayNext →

Why you'd press play

You want the clozapine and residual-symptom question answered without hand-waving, in a follow-up Q&A that stays clinically grounded.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Decera Clinical Education Neuroscience Podcast